Home › Research › Topics › amyloid-tau
amyloid-tau
7 studies tagged amyloid-tau, dated 2014-01-01 to 2024-07-03. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies 2024-07-03
- Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease 2022-12-01
- Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals 2022-08-18
Studies
7 studies carry this tag.
Date range
2014 to 2024
Top journals
- Alzheimer's research & therapy 2
- Alzheimer's & dementia : the journal of the Alzheimer's Association 1
- Brain : a journal of neurology 1
- Current Alzheimer research 1
- Frontiers in aging neuroscience 1
6 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Amyloid, tau, neurodegeneration and neuroinflammation plasma biomarkers are modified in DLB, albeit with moderate diagnosis performance.
-
50/100
Early-onset (age < 65) Alzheimer's disease is associated with greater non-amnestic cognitive symptoms and neuropathological burden than late-onset disease.
-
The levels of plasma ATN biomarkers (Aβ42/Aβ40 ratio, p-tua181, and NfL) were significantly changed in clinically diagnosed AD patients and they all associated with different domains of cognitive impairment.
-
RNT was associated with decline in cognitive domains affected early in AD and with neuroimaging AD biomarkers.
-
48/100
Concentrations of Aβ 40 and Aβ 42 were much higher in adults with DS than in other groups, reflecting APP gene triplication, while no difference in the Aβ 42 /Aβ 40 ratio between those with DS and sAD may indicate similar processing and deposition of Aβ 40 and Aβ 42 in these groups.
-
Alzheimer's Disease (AD) is age-related neurodegenerative disorder recognized by a steadily gradual cognitive decline that has devastating personal and socioeconomic implications.
-
Primary pathologies including amyloid-β (Aβ) plaques and neurofibrillary tangles (NFT) develop many years before the onset of dementia symptoms in Alzheimer's disease (AD).